Merck, Inc.
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension
- Conditions
- Interventions
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 112
- Registration Number
- NCT05523323
- Locations
- 🇨🇳
Shanghai East Hospital ( Site 3300), Shanghai, Shanghai, China
🇨🇳Henan Cancer Hospital ( Site 3309), Zhengzhou, Henan, China
🇨🇳Chongqing Cancer Hospital ( Site 3327), Chongqing, Chongqing, China
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
- Conditions
- Interventions
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 260
- Registration Number
- NCT05514444
- Locations
- 🇨🇦
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0201), Toronto, Ontario, Canada
🇺🇸The University of Louisville, James Graham Brown Cancer Center ( Site 0100), Louisville, Kentucky, United States
🇳🇱Amsterdam UMC, locatie VUmc ( Site 0400), Amsterdam, Noord-Holland, Netherlands
Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)
- Conditions
- Interventions
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1271
- Registration Number
- NCT05507450
- Locations
- 🇺🇸
Advanced Medical Research Institute ( Site 0115), Miami, Florida, United States
🇦🇺Emeritus Research ( Site 0009), Camberwell, Victoria, Australia
🇫🇮FVR, Porin rokotetutkimusklinikka ( Site 0033), Pori, Satakunta, Finland
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
- Conditions
- Interventions
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 360
- Registration Number
- NCT05508867
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center ( Site 0500), Guangzhou, Guangdong, China
🇺🇸The University of Arizona Cancer Center - North Campus ( Site 2216), Tucson, Arizona, United States
🇺🇸UCLA Hematology/Oncology - Santa Monica ( Site 2208), Los Angeles, California, United States
MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 20
- Registration Number
- NCT05494736
- Locations
- 🇷🇴
ARENSIA Exploratory Medicine-Institutul National de Boli Infectioase Matei Bals ( Site 0004), București, Bucuresti, Romania
🇿🇦Desmond Tutu Health Foundation ( Site 0001), Cape Town, Western Cape, South Africa
🇿🇦Josha Research ( Site 0003), Bloemfontein, Free State, South Africa
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 180
- Registration Number
- NCT05468697
- Locations
- 🇮🇱
Emek Medical Center-oncology ( Site 3003), Afula, Israel
🇮🇱Rambam Health Care Campus-Oncology ( Site 3000), Haifa, Israel
🇮🇱Shaare Zedek Medical Center-Oncology ( Site 3002), Jerusalem, Israel
A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)
- Conditions
- Interventions
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 48
- Registration Number
- NCT05466422
- Locations
- 🇺🇸
California Clinical Trials Medical Group managed by PAREXEL-PAREXEL International ( Site 0007), Glendale, California, United States
🇺🇸Collaborative Neuroscience Research, LLC ( Site 0009), Los Alamitos, California, United States
🇺🇸NRC Research Institute ( Site 0015), Orange, California, United States
A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2162
- Registration Number
- NCT05464420
- Locations
- 🇺🇸
L&C Professional Medical Research Institute ( Site 0012), Miami, Florida, United States
🇺🇸Desert Clinical Research/ CCT Research ( Site 0019), Mesa, Arizona, United States
🇺🇸Valley Clinical Trials, Inc. ( Site 0023), Northridge, California, United States
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
- Conditions
- Interventions
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 223
- Registration Number
- NCT05458297
- Locations
- 🇺🇸
Alaska Oncology and Hematology ( Site 0037), Anchorage, Alaska, United States
🇺🇸Banner MD Anderson Cancer Center ( Site 0040), Gilbert, Arizona, United States
🇺🇸University of Wisconsin Hospitals and Clinics-Carbone Cancer Center ( Site 0030), Madison, Wisconsin, United States
V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)
- Conditions
- Interventions
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1500
- Registration Number
- NCT05450705
- Locations
- 🇨🇳
Jiangshan Center for Disease Control and Prevention ( Site 0001), Quzhou, Zhejiang, China
🇨🇳Yuhuan Center for Disease Control and Prevention ( Site 0002), Taizhou, Zhejiang, China